Welcome to our dedicated page for Izotropic Canada news (Ticker: IZOZF), a resource for investors and traders seeking the latest updates and insights on Izotropic Canada stock.
Izotropic Corporation (OTCQB: IZOZF) is a medical device company developing the IzoView Breast CT Imaging System and related imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers. The Izotropic news feed on Stock Titan brings together company announcements and third-party coverage that explain how the company is advancing its breast imaging technology and commercialization plans.
News items for Izotropic often highlight progress around the IzoView Breast CT Imaging System, including the integration of a patent-pending radiation dose personalization feature that uses an optical pre-scan and proprietary software to calculate patient-specific radiation doses. Other coverage discusses the system’s compression-free, contact-free design and its focus on improving detection accuracy in women with dense breast tissue.
Investors and healthcare stakeholders can also find updates on Izotropic’s AI integration, such as its trade-secret machine-learning reconstruction algorithm, proprietary deep-learning reconstruction algorithm for image optimization, and exclusive rights to a U.S. patent for computer-aided diagnosis (CADx) with breast CT technology. Editorial features and interviews explore how these capabilities position IzoView within the evolving field of AI-enabled breast imaging.
Additional news includes the launch of educational resources like the BreastCT.com “Breast Imaging News” section, a podcast series on AI and the future of breast imaging, and a corporate FAQ page designed to improve transparency for investors, analysts, and healthcare decision-makers. Governance and corporate updates, such as Annual General and Special Meeting results and by-law amendments, also appear in the company’s news flow. Bookmark this page to review Izotropic’s ongoing disclosures, educational initiatives, and media coverage related to its breast imaging technology.
Izotropic (OTCQB:IZOZF) signed a Letter Agreement to form Izotropic Africa (Casablanca) with a business group to license, market, distribute, and evaluate manufacturing/assembly of IzoView Breast CT across Africa and the GCC. The parties agreed a 60/40 split (BG/Izotropic), target a Formal Agreement by April 30, 2026, and plan a Q1 2026 hospital installation in Morocco for research and regulatory engagement. Izotropic's estimated first-year share is USD $120K, with a USD $30K initial advance.
Izotropic (OTCQB: IZOZF) announced results of its Annual General and Special Meeting held on December 29, 2025. Shareholders approved the election of nominees to a five-member board, ratified the re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP, and approved a by-law amendment reducing the shareholder quorum requirement from 20% to at least 1% of issued voting shares. The quorum change preserves majority voting for decisions and was proposed in response to persistent mail delays, posting disruptions, and delays affecting shareholders using self-managed trading platforms. The company thanked shareholders for their participation and support.
Izotropic (OTCQB: IZOZF) released Episode 2 of its podcast series on November 12, 2025, titled “AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation.”
The episode explains how Izotropic integrates artificial intelligence into its IzoView Breast CT Imaging System, discusses a trade-secret machine-learning reconstruction algorithm, and notes the company’s exclusive U.S. patent rights for computer-aided diagnosis (CADx) with breast CT technology. The podcast is available in seven languages and aims to educate patients, clinicians, and stakeholders while supporting awareness as IzoView advances toward regulatory approval and market launch. Episode 2 is available now on the company YouTube channel.
Izotropic (OTCQB: IZOZF) announced on October 28, 2025 the launch of a new "Breast Imaging News" page on BreastCT.com.
The page will provide curated coverage of breast imaging developments, including clinical trials, peer-reviewed studies, mergers and acquisitions, and policy or insurance updates, with articles paired to clear takeaways and links to Izotropic's flagship IzoView Breast CT platform.
This addition is positioned as an educational and awareness resource tied to the company’s imaging technology.
Izotropic Corporation (OTCQB: IZOZF) announced placement in an editorial by NetworkNewsWire on October 24, 2025 highlighting AI-driven imaging firms targeting the breast cancer market.
The company is noted for its IzoView Breast CT Imaging System, a purpose-built 3D solution aimed at improving detection accuracy, especially in women with dense breast tissue. The release cites WHO and ACS data on global and U.S. breast cancer incidence to frame market demand.
Izotropic (OTCQB: IZOZF) released a CEO interview outlining near-term execution for its flagship IzoView dedicated breast CT platform.
Planned use of proceeds over the next 12–18 months includes funding for 3 IzoView devices, capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE‑mark activities, and two additional CE‑focused devices to build data and accelerate regulatory pathways. The CEO highlighted an exclusive CADx patent for breast CT and potential recurring revenues beyond device sales, and discussed regulatory, clinical, and market risks into 2026 with mitigation strategies.
Izotropic Corporation (OTCQB: IZOZF) announced placement in an editorial published by NetworkNewsWire on Oct 22, 2025, highlighting AI-enabled breast imaging and a projected $9 billion market for next‑gen 3D AI-imaging technologies.
The piece frames AI as a tool to improve early breast cancer detection and cites global statistics: 2.3 million diagnoses and ~670,000 deaths in 2022 (WHO) and 316,950 new invasive U.S. cases projected this year (ACS). The editorial spotlights Izotropic's IzoView Breast CT Imaging System, a dedicated 3D platform aimed at better detection for women with dense breast tissue.
Izotropic Corporation (OTCQB: IZOZF) was featured in CEO.CA's "Inside the Boardroom" interview on October 21, 2025, where CEO Robert Thast discussed the company's breast cancer technology and strategy.
The interview positions the technology as targeting 50% of women currently underserved by existing screening or diagnostic options and invites investors to view the full conversation via CEO.CA and YouTube. The piece also promotes CEO.CA as an investor social network with broad engagement and weekly executive interviews.
Izotropic (OTCQB: IZOZF) highlighted gaps in current breast imaging during Breast Cancer Awareness Month and positioned its IzoView Breast CT as a dedicated, true 3D adjunct for screening asymptomatic women with dense breasts. The company cited screening limits: ~20% cancers missed at mammography, 10–12% false negatives, and up to 50–60% of women experiencing a false positive within 10 years. Izotropic described IzoView as acquiring ~500 high-resolution images in ~10 seconds, reconstructing a true 3D volume, and targeting a device sales price of USD $500,000. The firm referenced market growth from USD $5.4B (2024) to $8.69B (2030, CAGR 8.25%) and research claims of breast CT offering markedly higher spatial resolution than MRI.
Izotropic (OTCQB: IZOZF) has published a new article on BreastCT.com highlighting the competitive advantages of its IzoView Breast CT Imaging System in AI-integrated breast imaging. The article emphasizes IzoView's purpose-built design for artificial intelligence integration, featuring a proprietary reconstruction algorithm and compression-free scanning capability that delivers high-quality 3D images in just 10 seconds.
The system, targeted at a USD $500K price point, addresses growing demand for advanced breast screening solutions, particularly for dense breast tissue. IzoView's architecture combines exclusive AI capabilities with scalable software features, positioning it as a future-ready platform in the evolving landscape of intelligent medical imaging.
["Purpose-built design for AI integration with proprietary reconstruction algorithm", "Fast 10-second compression-free scanning capability", "Competitive USD $500K target price point", "Specifically addresses dense breast tissue screening challenges"]